Cormorant Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Cormorant Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-900,000	Closed	-$11M	–	60
2017 Q3	$11M	Hold	900,000	–	–	1.95%	19
2017 Q2	$10.3M	Sell	900,000 -198,205	-18%	-$3.66M	1.71%	20
2017 Q1	$22.8M	Sell	1,098,205 -483,399	-31%	-$10.7M	3.32%	10
2016 Q4	$32.9M	Sell	1,581,604 -107,467	-6%	-$2.79M	4.43%	4
2016 Q3	$55.4M	Hold	1,689,071	–	–	6.1%	1
2016 Q2	$42.2M	Buy	1,689,071 +191,596	+13%	+$5.18M	5.98%	1
2016 Q1	$36.7M	Buy	1,497,475 +740,000	+98%	+$17.1M	5.52%	1
2015 Q4	$25M	Hold	757,475	–	–	2.99%	9
2015 Q3	$24.8M	Hold	757,475	–	–	3.96%	6
2015 Q2	$40.1M	Buy	757,475 +440,000	+139%	+$16M	5.33%	4
2015 Q1	$9.16M	Buy	317,475 +67,475	+27%	+$1.85M	1.42%	21
2014 Q4	$7.27M	Buy	250,000 +100,000	+67%	+$1.79M	1.12%	26
2014 Q3	$1.9M	Hold	150,000	–	–	0.39%	52
2014 Q2	$3.01M	Buy	+150,000	New	+$2.11M	0.8%	42

Other funds holding ALDR

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cormorant Asset Management's ALDR Position: Q4 2017 in Review

Cormorant Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2017, closing a stake of 900,000 shares — an estimated $11M sold.

Cormorant Asset Management first reported a position in ALDR in Q2 2014 and held it in 14 quarters. The position peaked at $55.4M in Q3 2016. 140 funds tracked by Wall St. Rank hold ALDR as of Q4 2017.

Cormorant Asset Management reported no remaining Alder Biopharmaceuticals position as of Q4 2017 after selling out during the quarter.
Cormorant Asset Management sold 900,000 Alder Biopharmaceuticals shares in Q4 2017, an estimated $11M.
Cormorant Asset Management first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 14 quarters.
Cormorant Asset Management's Alder Biopharmaceuticals position peaked at $55.4M in Q3 2016.
140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2017.

Based on Cormorant Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.